Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY)

59 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q2 2021.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 19.8M shares of 64.5M outstanding shares and own 30.66% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (2.44M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.18M shares), Sofinnova Investments, Inc. (2.03M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), Novo Holdings A/S (1.87M shares), Pivotal bioVenture Partners Investment Advisor LLC (1.59M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.29M shares), CHI Advisors LLC (927K shares), BlackRock Inc. (900K shares), and Rock Springs Capital Management LP (840K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.